Cargando…

Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy

AIM: Drug‐induced liver injury is one of the most serious adverse drug reactions and the most frequent reason for restriction of indications or withdrawal of drugs. Some nonsteroidal anti‐inflammatory drugs (NSAIDs) were withdrawn from the market because of serious hepatotoxicity. We estimated the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Donati, Monia, Conforti, Anita, Lenti, Maria Carmela, Capuano, Annalisa, Bortolami, Oscar, Motola, Domenico, Moretti, Ugo, Vannacci, Alfredo, Rafaniello, Concetta, Vaccheri, Alberto, Arzenton, Elena, Bonaiuti, Roberto, Sportiello, Liberata, Leone, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917796/
https://www.ncbi.nlm.nih.gov/pubmed/26991794
http://dx.doi.org/10.1111/bcp.12938
_version_ 1782438999530405888
author Donati, Monia
Conforti, Anita
Lenti, Maria Carmela
Capuano, Annalisa
Bortolami, Oscar
Motola, Domenico
Moretti, Ugo
Vannacci, Alfredo
Rafaniello, Concetta
Vaccheri, Alberto
Arzenton, Elena
Bonaiuti, Roberto
Sportiello, Liberata
Leone, Roberto
author_facet Donati, Monia
Conforti, Anita
Lenti, Maria Carmela
Capuano, Annalisa
Bortolami, Oscar
Motola, Domenico
Moretti, Ugo
Vannacci, Alfredo
Rafaniello, Concetta
Vaccheri, Alberto
Arzenton, Elena
Bonaiuti, Roberto
Sportiello, Liberata
Leone, Roberto
author_sort Donati, Monia
collection PubMed
description AIM: Drug‐induced liver injury is one of the most serious adverse drug reactions and the most frequent reason for restriction of indications or withdrawal of drugs. Some nonsteroidal anti‐inflammatory drugs (NSAIDs) were withdrawn from the market because of serious hepatotoxicity. We estimated the risk of acute and serious liver injury associated with the use of nimesulide and other NSAIDs, with a prevalence of use greater than or equal to 5%. METHODS: This is a multicentre case–control study carried out in nine Italian hospitals from October 2010 to January 2014. Cases were adults, with a diagnosis of acute liver injury. Controls presented acute clinical disorders not related to chronic conditions, not involving the liver. Adjusted odds ratio (ORs) with 95% confidence interval (CI) were calculated initially with a bivariate and then multivariate analysis. RESULTS: We included 179 cases matched to 1770 controls. Adjusted OR for acute serious liver injury associated with all NSAIDs was 1.69, 95% CI 1.21–2.37. Thirty cases were exposed to nimesulide (adjusted OR 2.10, 95% CI 1.28–3.47); the risk increased according to the length of exposure (OR > 30 days: 12.55, 95% CI 1.73–90.88) and to higher doses (OR 10.69, 95% CI 4.02–28.44). Risk of hepatotoxicity was increased also for ibuprofen, used both at recommended dosages (OR 1.92, 95% CI 1.13–3.26) and at higher doses (OR 3.73, 95% CI 1.11–12.46) and for ketoprofen ≥ 150 mg (OR 4.65, 95% CI 1.33–10.00). CONCLUSION: Among all NSAIDs, nimesulide is associated with the higher risk, ibuprofen and high doses of ketoprofen are also associated with a modestly increased risk of hepatotoxicity.
format Online
Article
Text
id pubmed-4917796
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-49177962016-11-04 Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy Donati, Monia Conforti, Anita Lenti, Maria Carmela Capuano, Annalisa Bortolami, Oscar Motola, Domenico Moretti, Ugo Vannacci, Alfredo Rafaniello, Concetta Vaccheri, Alberto Arzenton, Elena Bonaiuti, Roberto Sportiello, Liberata Leone, Roberto Br J Clin Pharmacol Pharmacoepidemiology AIM: Drug‐induced liver injury is one of the most serious adverse drug reactions and the most frequent reason for restriction of indications or withdrawal of drugs. Some nonsteroidal anti‐inflammatory drugs (NSAIDs) were withdrawn from the market because of serious hepatotoxicity. We estimated the risk of acute and serious liver injury associated with the use of nimesulide and other NSAIDs, with a prevalence of use greater than or equal to 5%. METHODS: This is a multicentre case–control study carried out in nine Italian hospitals from October 2010 to January 2014. Cases were adults, with a diagnosis of acute liver injury. Controls presented acute clinical disorders not related to chronic conditions, not involving the liver. Adjusted odds ratio (ORs) with 95% confidence interval (CI) were calculated initially with a bivariate and then multivariate analysis. RESULTS: We included 179 cases matched to 1770 controls. Adjusted OR for acute serious liver injury associated with all NSAIDs was 1.69, 95% CI 1.21–2.37. Thirty cases were exposed to nimesulide (adjusted OR 2.10, 95% CI 1.28–3.47); the risk increased according to the length of exposure (OR > 30 days: 12.55, 95% CI 1.73–90.88) and to higher doses (OR 10.69, 95% CI 4.02–28.44). Risk of hepatotoxicity was increased also for ibuprofen, used both at recommended dosages (OR 1.92, 95% CI 1.13–3.26) and at higher doses (OR 3.73, 95% CI 1.11–12.46) and for ketoprofen ≥ 150 mg (OR 4.65, 95% CI 1.33–10.00). CONCLUSION: Among all NSAIDs, nimesulide is associated with the higher risk, ibuprofen and high doses of ketoprofen are also associated with a modestly increased risk of hepatotoxicity. John Wiley and Sons Inc. 2016-04-27 2016-07 /pmc/articles/PMC4917796/ /pubmed/26991794 http://dx.doi.org/10.1111/bcp.12938 Text en © 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Pharmacoepidemiology
Donati, Monia
Conforti, Anita
Lenti, Maria Carmela
Capuano, Annalisa
Bortolami, Oscar
Motola, Domenico
Moretti, Ugo
Vannacci, Alfredo
Rafaniello, Concetta
Vaccheri, Alberto
Arzenton, Elena
Bonaiuti, Roberto
Sportiello, Liberata
Leone, Roberto
Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy
title Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy
title_full Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy
title_fullStr Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy
title_full_unstemmed Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy
title_short Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy
title_sort risk of acute and serious liver injury associated to nimesulide and other nsaids: data from drug‐induced liver injury case–control study in italy
topic Pharmacoepidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917796/
https://www.ncbi.nlm.nih.gov/pubmed/26991794
http://dx.doi.org/10.1111/bcp.12938
work_keys_str_mv AT donatimonia riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT confortianita riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT lentimariacarmela riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT capuanoannalisa riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT bortolamioscar riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT motoladomenico riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT morettiugo riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT vannaccialfredo riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT rafanielloconcetta riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT vaccherialberto riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT arzentonelena riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT bonaiutiroberto riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT sportielloliberata riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT leoneroberto riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly
AT riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly